207279-29-6

Basic information

• Product Name: 8-Methoxy-1,7-naphthyridin-6-yl trifluoroMethanesulfonate
• Synonyms: 8-Methoxy-1,7-naphthyridin-6-yl trifluoroMethanesulfonate
• CAS NO: 207279-29-6
• Molecular Formula: C₁₀H₇F₃N₂O₄S
• Molecular Weight: 308.2337896
• Mol File: 207279-29-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-Methoxy-1,7-naphthyridin-6-yl trifluoroMethanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Methoxy-1,7-naphthyridin-6-yl trifluoroMethanesulfonate(207279-29-6)
• EPA Substance Registry System: 8-Methoxy-1,7-naphthyridin-6-yl trifluoroMethanesulfonate(207279-29-6)

Safety Data

• Hazardous Substances Data: 207279-29-6(Hazardous Substances Data)

Upstream product

• 5912-34-5 2-cyano-pyridin-3-yl-acetonitrile 
• 1493-13-6 trifluorormethanesulfonic acid 
• 55716-28-4 8-methoxy-[1,7]naphthyridin-6-ylamine 

Downstream Products

• 1201843-34-6 N-(2-chloro-5-(8-methoxy-1,7-naphthyridin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 207279-30-9 6-(4-carboxyphenyl)-8-methoxy-1,7-naphthyridine 
• 426268-06-6 RO-458,2640 
• 207279-31-0 6-(4-carboxyphenyl)-8-bromo-1,7-naphthyridine 

Relevant articles and documents

Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: A potent and selective phosphodiesterase type 4D inhibitor

The synthesis of a 6,8-disubstituted 1,7-naphthyridine 1 and its characterization as a potent and selective phosphodiesterase type 4D inhibitor (IC50=1.5nM) are described. The compound inhibited TNFα-release from human peripheral blood mononuclear cells and was orally active in a model of adjuvant-induced arthritis in rats.

Naphthyridine derivatives

PCT No. PCT/EP97/05898 Sec. 371 Date Apr. 27, 1999 Sec. 102(e) Date Apr. 27, 1999 PCT Filed Oct. 24, 1997 PCT Pub. No. WO98/18796 PCT Pub. Date May 7, 1998Novel 8-aryl-1,7-naphthyridines, in free or salt form, are PDE IV inhibitors and are thus useful as pharmaceuticals, e.g. for asthma therapy. Preferred compounds include compounds of formulae (I and II) wherein the R groups are as defined. Pharmaceutical compositions comprising the compounds, processes for preparation of the compounds and novel intermediates for use in the processes are disclosed.